NEW YORK CITY, NY / ACCESS Newswire / March 11, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. ("Elevance" or "the Company") (NYSE:ELV). Investors who purchased Elevance securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ELV.
Elevance Investigation Details
On March 2, 2026, Elevance disclosed in a filing with the U.S. Securities and Exchange Commission that it "was notified by the Centers for Medicare & Medicaid Services (‘CMS’) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (‘MA-PD’) plans and suspending certain communication activities to Medicare beneficiaries." Elevance said that "CMS has indicated that the proposed sanctions relate to alleged noncompliance by the Company with certain Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023" and that "[t]he sanctions are scheduled to take effect on March 31, 2026 unless CMS determines that the issues identified have been satisfactorily addressed." Following this news, Elevance’s stock price fell $25.93 per share, or 8.1%, to close at $294.07 on March 2, 2026.
What’s Next for Elevance Investors?
If you are aware of any facts relating to this investigation or purchased Elevance securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ELV. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Elevance Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Elevance Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_475063917/2457/2026-03-11T11:02:51